Recombinant LAG3 antibody

Catalog No. ABIN7881490

The Rabbit Monoclonal anti-LAG3 antibody is suitable to detect LAG3 in samples from Human. It has been validated for IHC, ICC and IF.

Quick Overview for Recombinant LAG3 antibody (ABIN7881490)

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This LAG3 antibody is un-conjugated

Application: Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunofluorescence (IF)

Clone: 31L58

Product Details anti-LAG3 Antibody

Purpose: LAG-3 Antibody / Lymphocyte activation gene 3 protein / CD223

Purification: Affinity-chromatography

Immunogen: A synthesized peptide derived from human CD223 was used as the immunogen for the LAG-3 antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the LAG-3 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol, 0.4-0.5 mg/mL BSA

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store the LAG-3 antibody at -20oC.

Target Details for LAG3

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Alternative Name: LAG-3

Background: LAG-3 antibody detects lymphocyte activation gene 3 protein, an immune checkpoint receptor encoded by the LAG3 gene. LAG-3 is expressed on activated T cells, natural killer cells, and plasmacytoid dendritic cells. It binds MHC class II molecules and negatively regulates T cell proliferation and activation. This checkpoint function maintains immune tolerance and prevents autoimmunity, but also contributes to immune evasion in cancer.

LAG-3 antibody is widely applied in immunology, oncology, and translational research. In cancer, LAG-3 expression marks exhausted T cells within the tumor microenvironment. In chronic infection, sustained LAG-3 expression dampens antiviral responses. By detecting LAG-3, researchers can evaluate immune exhaustion, tolerance mechanisms, and therapeutic checkpoint blockade strategies.

Flow cytometry with LAG-3 antibody identifies exhausted or regulatory T cell subsets. Immunohistochemistry maps LAG-3 expression in tumors and inflamed tissues, while immunofluorescence highlights surface distribution on lymphocytes. Western blotting confirms expression in activated immune cell lysates. These methods enable detailed characterization of immune checkpoint biology.

LAG-3 has therapeutic relevance as a target for immune checkpoint inhibitors. Antibodies blocking LAG-3 restore T cell function and enhance antitumor immunity. Clinical trials are evaluating LAG-3 blockade alone and in combination with PD-1 inhibitors. By applying LAG-3 antibody, scientists can monitor expression as a biomarker for patient selection and therapeutic response.

LAG-3 is also involved in autoimmune disease and transplantation. It modulates T regulatory cell function and dendritic cell activation, influencing tolerance and graft survival. Studying LAG-3 with antibody based methods provides insights into balancing immunity and tolerance in clinical settings.

LAG-3 antibody from NSJ Bioreagents provides strong specificity for detecting this checkpoint receptor. Its performance across multiple assays supports both basic and translational research in immunology and cancer therapy.

UniProt: P18627

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints